Financials data is unavailable for this security.
View more
Year on year Haleon PLC had little change in net income (from 1.06bn to 1.05bn) despite revenues that grew 4.09% from 10.86bn to 11.30bn.
| Gross margin | 61.94% |
|---|---|
| Net profit margin | 10.12% |
| Operating margin | 18.02% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in GBPView more
In 2023, Haleon PLC increased its cash reserves by 62.68%, or 383.00m. The company earned 2.10bn from its operations for a Cash Flow Margin of 18.58%. In addition the company used 134.00m on investing activities and also paid 1.57bn in financing cash flows.
| Cash flow per share | 0.0685 |
|---|---|
| Price/Cash flow per share | 47.23 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in GBPView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in GBP
Year on year, growth in dividends per share increased 150.00% while earnings per share excluding extraordinary items fell by -1.29%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend.
| Div yield(5 year avg) | 0.52% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 35.83% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -2.31 |
More ▼
